Alefacept Pregnancy and Breastfeeding Warnings

Brand names: Amevive

Alefacept Pregnancy Warnings

Alefacept has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal any evidence of fetal toxicity including adverse effects on immune system development. There are no controlled data in human pregnancy. Alefacept should be given during pregnancy when need has been clearly established.

Women of childbearing potential make up a considerable segment of the patient population affected by psoriasis.

Because the effect of alefacept on pregnancy and fetal development is not known, health care providers are encouraged by Biogen to enroll patients currently taking alefacept who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).

See references

Alefacept Breastfeeding Warnings

There are no data on the excretion of alefacept into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions due to alefacept in nursing infants, a decision should be made to discontinue nursing or discontinue the use of the drug, taking into account the importance of the drug to the mother.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer